Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis

Condition:   Raynaud's Phenomenon Secondary to Systemic Sclerosis Interventions:   Drug: Placebo IV infusion;   Drug: Iloprost Injection, for intravenous use Sponsor:   Eicos Sciences, Inc. Not yet recruiting

Source: ClinicalTrials.gov - July 31, 2019 Category: Research Source Type: clinical trials